Margarethe Konik

TL;DR: In this article, the authors evaluated the safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical(requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.

TL;DR: The data disprove the hypothesis of insufficient SARS-CoV-2-reactive immunity in critical COVID-19 and indicates that activation of differentiated memory effector T cells could cause hyper-reactivity and immunopathogenesis in critical patients.

TL;DR: This work investigated STS after TM‐ILP with a primary emphasis on histologic regression patterns, and found some tumors show an insufficient association between radiological and pathological response.

TL;DR: In this article, the effect of SARS-CoV-2 on altering the gut microbiome and the relevance of the Gut microbiome on COVID-19 severity needs to be clarified.

TL;DR: Data on S-protein reactive polyfunctional T cells indicate the ability of ARDS patients to generate antiviral protection, and decreased frequencies of activated memory/effector T cells expressing tissue migratory molecule CD11a++ observed in circulation of AR DS patients might suggest their involvement in ARDS development and proposeCD11a-based immune signature as a possible prognostic marker.